# Business Ideas — Based on Existing Assets

## What We Have

- **Nexotype** — Gene/Protein/Disease/Treatment knowledge graph (PostgreSQL + SurrealDB)
- **AssetManager (Finpy)** — VC/PE platform, cap table management
- **Finpy Scripts** — Financial data, trading analysis
- **Infrastructure** — FastAPI, Coolify, SurrealDB, graph databases

---

## Idea 1: Biotech Stock Intelligence Tool

**What:** Financial terminal for biotech stocks that overlays biological intelligence on market data.

**How it works:**
- Pull biotech stock data (Finpy scripts already do this)
- Map each company's drug pipeline to Nexotype's gene/disease graph
- Score pipeline strength based on biological target quality, competition, clinical stage
- Alert when FDA decisions, trial results, or competitor moves affect a stock

**Who pays:** Biotech-focused hedge funds, retail traders, equity analysts.

**Why it's good:**
- Finpy already handles financial data
- Nexotype already has the biological graph
- Connecting the two is the unique value — nobody else does this
- Can start small: a dashboard or newsletter

**Revenue:** $50–$500/month subscription depending on tier.

---

## Idea 2: Biotech Data API (SaaS)

**What:** API that lets other companies query our knowledge graph programmatically.

**How it works:**
- Expose Nexotype's graph via REST/GraphQL API
- Queries like: "What genes are associated with Alzheimer's?" or "What treatments target BRCA1?"
- Tiered access: free tier (limited queries), paid tier (full access + bulk export)

**Who pays:** Biotech startups, academic researchers, pharma R&D teams, AI/ML companies training models.

**Why it's good:**
- The data already exists in Nexotype
- API-first is low overhead (no UI to build initially)
- Recurring revenue from API calls
- Similar model to PubChem API but with graph relationships

**Revenue:** $100–$5,000/month based on usage tiers.

---

## Idea 3: B2B Market Intelligence Platform (Delphi Model)

**What:** Enterprise dashboard for pharma/biotech investors — same playbook as Delphi Data Labs but for biotech instead of hydrogen.

**How it works:**
- Map which companies target which gene targets / diseases
- Show competitive landscape per disease area
- Identify M&A targets (small biotechs with strong pipelines)
- Track clinical trials overlaid on biological knowledge graph
- VC/PE deal flow analysis

**Who pays:** Pharma BD teams, biotech VCs/PE, investment banks, strategy consultants.

**Market size:** Global pharma ~$1.5T, biotech ~$500B (vs Delphi's hydrogen/cleantech ~$200B).

**Competitors:**

| Company | Focus | Weakness |
|---|---|---|
| Evaluate Pharma | Drug pipeline valuations | No graph-based intelligence |
| Clarivate (Cortellis) | Drug pipeline + patents | Expensive, legacy UI |
| PitchBook / CB Insights | VC/PE deal data | No biological data layer |
| GlobalData | Broad pharma intelligence | Generic, not graph-native |

**Gap:** None of them combine biological knowledge graphs with company/financial data.

**Differentiation:**
1. Graph-native — Gene → Disease → Treatment → Company → Clinical Trial → Market, all connected
2. Biology + Business — Nexotype's biological graph merged with AssetManager's financial/VC data
3. Modern stack — FastAPI, SurrealDB, real-time updates vs legacy enterprise platforms

**Path forward:**
- Phase 1: Extend Nexotype models (Company, ClinicalTrial, Patent, FundingRound), build scrapers for ClinicalTrials.gov / FDA / SEC, connect AssetManager entities
- Phase 2: Disease landscape view, company profile pages, M&A target scoring
- Phase 3: Talk to Delphi friend for enterprise sales advice, find 3-5 potential users, validate willingness to pay
- Phase 4: "Request a demo" model, quarterly market reports (lead gen), enterprise pricing tiers

**Risks:**
- Data acquisition is the hardest part (company pipelines, partnerships, funding)
- Enterprise sales cycle is slow (6-12 months for pharma)
- Incumbents have decades of data and relationships
- Need to find what Evaluate/Clarivate underserve rather than competing head-on

**Key advantage:** Friend at Delphi has done this exact playbook in an adjacent industry. That connection is worth more than any technical advantage.

**Revenue:** $10k–$50k/year per customer.

---

## Idea 4: Consumer Longevity Platform

**What:** Personalized longevity recommendations based on user's genetics and biomarkers.

**How it works:**
- User uploads 23andMe / WGS data
- Map variants to longevity pathways (mTOR, AMPK, sirtuins, etc.)
- Recommend supplements, peptides, lifestyle changes based on genetic profile
- Track biomarkers over time, measure intervention efficacy

**Who pays:** Biohackers, longevity enthusiasts, longevity clinics (white-label).

**Competitors:** InsideTracker ($589/yr), Function Health ($499/yr), Viome ($400+).
**Our edge:** Graph-based personalized discovery vs static reports.

**Pricing tiers:**
- Premium $99/mo — Genetics upload, pathway analysis (22 pathways), personalized recommendations, biomarker tracking
- Pro $199/mo — Advanced graph discovery, peptide therapy recs, wearable/lab integration, practitioner access
- Enterprise $999+/mo — White-label for clinics, multi-patient management, custom pathway models, API access

**Revenue projections:** Conservative 1,000 users x $99 = $1.2M ARR. Aggressive 10,000 users x $149 = $17.9M ARR.

**Current assets (80% complete):** Gene/protein/pathway database, treatment/biomarker/enhancement tracking, graph database for relationship discovery, disease associations, peptide database.

**Required additions:**
1. Longevity pathway mapping — 22 pathways mapped to genes, tier classification (S/A/B/C/D), treatments linked to targets
2. Genetics processing — Upload handler for 23andMe/VCF, variant annotation pipeline, pathway impact scoring
3. Recommendation engine — Graph queries matching user variants to pathways to treatments
4. Biomarker tracking — Time-series storage, pathway health scores, intervention efficacy

**Core recommendations the platform would deliver:**
- Supplements: NMN/NR (NAD+), Metformin/Berberine (AMPK), Resveratrol (sirtuins), Rapamycin analogs (mTOR)
- Peptides: Epithalon (telomeres), MOTS-c (mitochondria), GHK-Cu (tissue repair), Thymosin Beta-4 (inflammation)
- Lifestyle: Fasting protocols (insulin/IGF-1), exercise plans (AMPK/mitochondrial), sleep optimization (circadian genes)
- Biomarkers: HbA1c, fasting insulin (Tier S), NAD+/NADH ratio (Tier S), hs-CRP, IL-6 (Tier A), Homocysteine (Tier C)
- Advanced: Senolytics, NAD+ IV therapy, hyperbaric oxygen, stem cell therapies

**Differentiation:**
- Generic platforms: "Take these 50 longevity supplements"
- Our platform: "Your NMNAT1 variant reduces NAD+ synthesis. Prioritize NMN 500mg over NR based on your genetics. Track NAD+/NADH ratio monthly."

**MVP strategy:**
- Phase 1: Focus on Tier S pathways (Insulin/IGF-1, mTOR, AMPK, Sirtuins = 60% impact), genetics upload + variant annotation, launch at $49/mo beta
- Phase 2: Validate with 10-100 beta users, content marketing, biohacker influencer partnerships
- Phase 3: Add Tier A pathways, biomarker dashboard, increase to $99/mo, B2B outreach to clinics

**Risks:**
- Regulatory: Health claims regulation — mitigate with wellness framing, disclaimers, health law attorney
- Data quality: Longevity science evolving — mitigate with peer-reviewed citations, continuous curation
- Competition: Market heating up — mitigate with graph DB moat, first-mover on personalized discovery
- Privacy: HIPAA compliance for genetic data — mitigate with encryption, SOC2, user data controls

**Commercial viability: 7/10** — Proven demand, 80% tech ready, unique differentiation, high margins. Cons: regulatory complexity, scientific curation overhead, niche user acquisition, HIPAA costs.

**Revenue:** $99–$999/month depending on tier.

---

## Quick Comparison

| Idea | Customer | Revenue/Customer | Effort to MVP | Risk |
|---|---|---|---|---|
| Biotech Stock Intelligence | Traders, analysts | $50–$500/mo | Medium | Market data costs |
| Biotech Data API | Developers, researchers | $100–$5k/mo | Low | Monetization unclear |
| B2B Market Intelligence | Pharma, VCs | $10k–$50k/yr | High | Enterprise sales cycle |
| Consumer Longevity | Biohackers, clinics | $99–$999/mo | Medium | Regulatory, HIPAA |

---

## Recommendation

**Fastest to revenue:** Biotech Data API — lowest effort, data already exists, API-first.

**Highest revenue potential:** B2B Market Intelligence — enterprise pricing, Delphi friend as advisor.

**Best product-market fit signal:** Consumer Longevity — proven demand, growing audience.

**Most unique:** Biotech Stock Intelligence — nobody combines biological graph data with stock analysis.
